Breast cancer Breast neoplasm, Chemotherapy, Peripheral Neuropathies
Conditions
Interventions
Pregabalin or mirogabalin will be administered as therapeutic agents for peripheral neuropathy.
D000068654, D000074570
Pregabalin, Mirogabalin
Sponsors
Kuba Sayaka
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients who have received perioperative chemotherapy for breast cancer and have developed chemotherapy-induced peripheral neuropathy (CIPN). 2) Patients who are able to complete a patient diary and questionnaire survey. 3) Patients aged between 18 and 80 years at the time of obtaining informed consent. 4) Patients who have provided written informed consent to participate in the study.
Exclusion criteria
Exclusion criteria: 1) Patients who have peripheral neuropathy prior to the initiation of chemotherapy. 2) Patients who are currently taking pregabalin or mirogabalin besilate. 3) Patients who are pregnant or breastfeeding. 4) Patients who are currently participating in another clinical trial or clinical study. 5) Patients whom the principal investigator or subinvestigator deems inappropriate for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NRS (Numerical Rating Scale) | — |
Secondary
| Measure | Time frame |
|---|---|
| CTCAE ver6.0, PRO-CTCAE | — |
Contacts
Public ContactSayaka Kuba
Nagasaki University Hospital
Outcome results
None listed